A serologic weak-D phenotype is defined as weak reactivity of RBCs with anti-D reagent in initial testing, less than expected for the applied serologic method. 4 In the immunohematological routine of blood donors, identifying individuals with very weak-D phenotype is encouraged, as the correspondent RBC unit must be labeled as Dpositive, minimizing the risks of anti-D development by recipients. Based on the exposed, our aim was to evaluate the distribution of RHD variant genotype among blood donors and recipients with serologic weak-D phenotype of both African and European descent.
| ME THODS

| Donor and patient recruiting
Blood donors were sequentially recruited as they donated whole- The genetic ancestry of the studied donor population has been previously characterized using the FYB*-67T/C polymorphism (rs 2814778) as an informative marker of African ancestry. 12 The mu- 
| Nucleic acid purification
DNA was individually extracted from all selected samples using the PureLink Genomic Kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions. Purity and concentration of the material were evaluated by spectrophotometry (Nanodrop1000 Spectrophotometer, Wilmington, DE, USA). DNA samples were diluted to a final concentration of 100 ng/mL for RHD genotyping.
| RHD genotyping
Initial molecular analyses aiming to identify possible partial and weak RHD alleles were performed by amplifying RHD exons 3-7 and 9, using gene-specific primers, as described elsewhere. 13 All samples were genotyped for RHD*Ψ, RHC, and RHc 14 and also had the RHD zygosity confirmed using two different conventional PCR-based methods designed to detect the RHD deletion 15, 16 and also a multiplex real-time quantitative PCR approach. 15 When the sample was homozygous for RHD and genotyped RHCE*ce/RHCE*ce, the multiplex PCR RHC/RHc/hex3 was performed aiming to detect the presence of r'S haplotype. 17 PCRs using sequence-specific primers (PCR-SSP) designed to detect some weak D types (D weak types 2, 3, 4, and 5) were applied for all included samples. 18 In situations where the altered RHD genotype could not be confirmed based on the conventional molecular methods, the direct sequencing of RHD whole-coding regions was performed.
| RHD direct sequencing
All RHD exons and short flanking intron sequences were amplified using gene-specific primers. 19 Direct sequencing was performed by standard Sanger methodology using the cycle sequencing kit (ABI BigDye Terminator v3.1, Applied Biosystems) and run on automated sequencer equipment (ABI 310, Applied Biosystems), as previously described. 19 
| RE SULTS
| RHD genotyping of blood donors with weak-D phenotype
One hundred and six donors were included in the study, all typing as D-positive with low antigen expression (≤2+ reactivity with anti-D in initial testing using gel method or in confirmatory testing using solidphase method). All participants were genotyped for RHD/RHCE and classified as R 1 r (CcDdee) (47 donors, 44.3%); R 0 r (ccDdee) (25 donors, 23.6%); R 1 R 0 (CcDDee) (10 donors, 9.4%); R 0 R 0 (ccDDee) (8 donors, 7.5%); R 2 r (ccDdEe) (7 donors, 6.6%); R 2 R 0 (ccDDEe) (3 donors, 2.8%); could lead to anti-D alloimmunization following incompatible transfusions or pregnancies.
| Serological data of the donors with altered RHD genotype
All studied samples were tested either by Capture-R solid-phase technology (NEO, Immucor, Norcross, GA) or gel methodology (IH-1000;
Bio-Rad, Cressier, Switzerland). The intensity of reactions is shown in Table 2 ). This allele has been previously described by Garcia F, 2015. 20 It was named RHD*01N.58, and the corresponding phenotype was Dnegative by adsorption and elution test. And so, this donor was summoned for result confirmation. 
| RHD genotyping of patients with weak-D phenotype
| D ISCUSS I ON
This study describes the distribution of altered RHD alleles encod- The reactions considered for Neo (Immucor) refer to the confirmatory testing using solid-phase method. In the case of IH-1000 (Bio-Rad), the reactions refer to the initial testing using gel method. The present study also shed light into some important information for the immunohematological routine of mixed blood donors.
The most important one refers to the need for applying ultra- This study has some limitations. The most important one refers to the fact that there is a wide variation in the contribution of African ancestry in different mixed populations. And so, the conclusions drawn from the present study are applicable to populations where the racial ancestry is similar to Brazilian. On the other hand, the greatest strength of this study is that it sheds to light the need for having specific transfusion guidelines to meet the needs of mixed patients with serologic weak-D phenotype.
One proposed transfusion policy, based on our results, is shown in 
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